Advertisement

Topics

Latest "Biopure Corporation" News Stories

13:36 EST 13th December 2017 | BioPortfolio

Here are the most relevant search results for "Biopure Corporation" found in our extensive news archives from over 250 global news sources.

More Information about Biopure Corporation on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Biopure Corporation for you to read. Along with our medical data and news we also list Biopure Corporation Clinical Trials, which are updated daily. BioPortfolio also has a large database of Biopure Corporation Companies for you to search.

Showing "Biopure Corporation" News Articles 1–25 of 330

Relevant

BioPure Q-Clamp is compatible with a wide range of connector geometries


CombiMatrix Corporation Reminds Shareholders to Vote "FOR" the Merger With Invitae Corporation

IRVINE, Calif., Nov. 02, 2017 (GLOBE NEWSWIRE) -- CombiMatrix Corporation (NASDAQ:CBMX) ("CombiMatrix" or the "Company"), a family health molecular diagnostics company specializing in DNA-based reproductive health and pediatric testing services, reminds its shareholders to vote “FOR” the proposed merger with Invitae Corporation as described in the Company’s proxy statement/prospectus fo...

CombiMatrix Corporation Stockholders Approve Merger Agreement With Invitae Corporation

IRVINE, Calif., Nov. 10, 2017 (GLOBE NEWSWIRE) -- CombiMatrix Corporation (NASDAQ:CBMX) ("CombiMatrix" or the "Company"), a family health molecular diagnostics company specializing in DNA-based reproductive health and pediatric testing services, announced today that, based upon the final vote count for the Company’s Special Meeting of Stockholders held today, a majority of its stockholders ...


New gasket and braided hose range from BioPure sets the new standard for confident fluid path validation

Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend CombiMatrix Corporation Shareholders Vote "FOR" the Proposed Merger with Invitae Corporation

IRVINE, Calif., Nov. 01, 2017 (GLOBE NEWSWIRE) -- CombiMatrix Corporation (NASDAQ:CBMX) ("CombiMatrix" or the "Company"), a family health molecular diagnostics company specializing in DNA-based reproductive health and pediatric testing services, today announced that Institutional Shareholder Services Inc. (ISS) and Glass, Lewis & Co., LLC (Glass Lewis) have both recommended that CombiMatr...

Watson-Marlow Fluid Technology GroupNew Gasket And Braided Hose Range From Biopure Sets The New Standard For Confident Fluid Path Validation

  Life Sciences Jobs   ...

Orion Corporation: Managers' transactions - Hilpi Rautelin

ORION CORPORATION      MANAGERS' TRANSACTIONS 1st of November 2017 at 22.15 EET              Orion Corporation: Managers' transactions - Hilpi Rautelin Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their ...

Ventripoint Announces Results of Annual Shareholders' Meeting and Grant of Options and DSUs

TORONTO, ONTARIO -- (Marketwired) -- 08/16/17 -- Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Corporation") (TSX VENTURE: VPT) announces that at its Annual General Meeting on August 14, 2017 the shareholders re-elected Dr. George Adams, Mr. Danny Dalla-Longa, Dr. Alan Rabinowitz, Dr. Don Segal and Mr. David Willis as Directors of the Corporation. They further approved the Incentive Stock ...

Gregory B. Brown M.D. Appointed to the Board of Directors of Cambrex Corporation

EAST RUTHERFORD, N.J., Nov. 03, 2017 (GLOBE NEWSWIRE) -- Cambrex Corporation (NYSE:CBM), a leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), today announced that Gregory B. Brown, M.D. was appointed to the Company’s Board of Directors on October 31, 2017, and will serve on the Board’s Audit and Regulatory Affairs Committees.  Dr. Brown...

Mitsubishi Tanabe Pharma Corporation Completes Acquisition of NeuroDerm

REHOVOT, Israel, Oct. 18, 2017 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drug-device combinations for central nervous system (CNS) disorders, announced today the completion of the previously announced acquisition of NeuroDerm by Mitsubishi Tanabe Pharma Corporation (TSE Code: 4508), a publicly traded company on the Tokyo Stock Exchang...

Geron Corporation Reports Third Quarter 2017 Financial Results

MENLO PARK, Calif., Nov. 01, 2017 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today reported financial results for the three and nine months ended September 30, 2017. For the third quarter of 2017, the company reported a net loss of $6.9 million, or $0.04 per share, compared to $3.6 million, or $0.02 per share, for the comparable 2016 period. Net loss for the first nine months o...

CombiMatrix Corporation Reports Third Quarter 2017 Financial and Operating Results

IRVINE, Calif., Nov. 06, 2017 (GLOBE NEWSWIRE) -- CombiMatrix Corporation (NASDAQ:CBMX), a family health molecular diagnostics company specializing in DNA-based reproductive health and pediatric testing services, announces financial and operating results for the three and nine months ended September 30, 2017. 

ICC International Cannabis Corporation Provides Cannabinoid Extract Business Segment Update

Highlights:

NeuroDerm Shareholders Approve Proposed Acquisition by Mitsubishi Tanabe Pharma Corporation

REHOVOT, Israel, Sept. 12, 2017 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drug-device combinations for central nervous system (CNS) disorders, announced that at NeuroDerm’s extraordinary general meeting of shareholders held today, NeuroDerm shareholders voted to approve the previously announced acquisition by Mitsubishi Tanabe Pharm...

International Stem Cell Corporation Doses 7th Patient in Clinical Trial for Parkinson's Disease

CARLSBAD, Calif., Nov. 29, 2017 (GLOBE NEWSWIRE) -- International Stem Cell Corporation (OTCQB:ISCO) (www.internationalstemcell.com) (“ISCO” or “the Company”), a California-based clinical stage biotechnology company developing novel stem cell-based therapies and biomedical products reported today that a third patient of the second cohort with Parkinson's disease was successfully trans...

Orthobond Corporation to Present at the 2017 North American Spine Society Annual Meeting

NORTH BRUNSWICK, N.J., Oct. 23, 2017 (GLOBE NEWSWIRE) -- Orthobond Corporation (North Brunswick, NJ), a leader in the design and development of antimicrobial implant surfaces, has been invited to participate in a focused session on occult infections in the spine at the 2017 North American Spine Society (NASS) Annual Meeting. The annual NASS meeting is the largest gathering of spine surgeons i...

Stryker increases dividend 11%, declaring a $0.47 per share quarterly dividend

Kalamazoo, Michigan - December 6, 2017 - Stryker Corporation (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.47 per share payable on January 31, 2018 to shareholders of record at the close of business on December 29, 2017, representing an increase of approximately 11% versus the prior year and the previous quarter.  "Our financial st...

International Stem Cell Corporation Announces Operating Results for the Three and Nine-Months ended September 30, 2017

CARLSBAD, Calif., Nov. 17, 2017 (GLOBE NEWSWIRE) -- International Stem Cell Corporation (OTCQB:ISCO) (www.internationalstemcell.com) (“ISCO” or “the Company”), a California-based clinical stage biotechnology company developing novel stem cell-based therapies and biomedical products, today provided a business update and announced operating results for the three and nine months ending o...

International Stem Cell Corporation Reports Progress in Phase I Clinical Trial for Parkinson's Disease

CARLSBAD, Calif., Sept. 07, 2017 (GLOBE NEWSWIRE) -- International Stem Cell Corporation (OTCQB:ISCO), a California-based clinical stage biotechnology company developing stem cell-based therapies and biomedical products, today reported that two more patients with Parkinson’s disease were successfully transplanted with ISCO’s proprietary ISC-hpNSC® cells at the Royal Melbourne Hospital (R...

Advanced Proteome Therapeutics Corporation Completes Rights Offering for Gross Proceeds of Approximately $430,000

VANCOUVER, BRITISH COLUMBIA -- (Marketwired) -- 07/11/17 -- Advanced Proteome Therapeutics Corporation ("APC" or the "Company") (TSX VENTURE: APC)(FRANKFURT: 0E8) is pleased to report that it has completed its previously announced rights offering (the "Rights Offering"). Under the Rights Offering, on July 10, 2017, 7,136,216 units of the Corporation (the "Units") were distributed at a price of ...

International Stem Cell Corporation to Move Forward with Traumatic Brain Injury Phase II Clinical Trial

CARLSBAD, Calif., Sept. 20, 2017 (GLOBE NEWSWIRE) -- International Stem Cell Corporation (OTCQB:ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"), a California-based clinical stage biotechnology company developing novel stem cell-based therapies and biomedical products, announced today that the completion of its preclinical studies in Traumatic Brain Injury (TBI) program will po...

AntriaBio Announces Exclusive License Agreement for a Phase 2 Orphan Disease Therapy with XOMA Corporation and Name Change to Rezolute, Inc.

LOUISVILLE, Colo., Dec. 07, 2017 (GLOBE NEWSWIRE) -- Rezolute, Inc. (“Rezolute” or the “Company”) (OTCQB:ANTB), a clinical stage biopharmaceutical company specializing in the development of innovative drug therapies for metabolic and orphan diseases, and XOMA Corporation (“XOMA”) (NASDAQ:XOMA), a pioneer in the discovery, development and licensing of therapeutic antibodies, announ...

ALGAE DYNAMICS CORP SECURES US $250,000 INVESTMENT FROM TEEWINOT LIFE SCIENCES CORPORATION

Toronto, ON, Nov. 15, 2017 (GLOBE NEWSWIRE) Read more...

International Stem Cell Corporation to Expand its Revenue Generating Biomedical Businesses to Support Ongoing and Future Clinical Trials

H1 2017 operating income from ISCO’s revenue generating subsidiaries demonstrated an increase of 51% compared to its income in H1 2016, while H1 2017 revenue was $3.8 million. Edison Investment Research target price for ISCO shares is $6.62 per share* CARLSBAD, Calif., Sept. 26, 2017 (GLOBE NEWSWIRE) -- International Stem Cell Corporation (OTCQB:ISCO)  (www.internationalstemcell.com) ("...

UNITED THERAPEUTICS CORPORATION (UTHR) INVESTOR ALERT: Legal Investigation for Potential ...

Girard Gibbs LLPEileen Epstein, 510-350-9728EJE@CLASSLAWGROUP.COM Read more...


Quick Search
Advertisement
 

News Quicklinks